Journal of Cancer Research and Clinical Oncology

, Volume 141, Issue 12, pp 2131–2138 | Cite as

Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973–2011

  • Melissa A. Deadmond
  • Julie A. Smith-GagenEmail author
Original Article – Cancer Research



Recent diagnostic and cancer reporting changes influencing myeloproliferative neoplasms (MPNs) encourage the assessment of trends and examination of the recently identified MPN subtypes: polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), across the age continuum by race and ethnicity.


Surveillance, Epidemiology, and End Results data provided MPN incidence data since 1973 and MPN subtype data since 2001. Joinpoint regression estimated annual percent changes. Poisson regression estimated risk ratios.


The 2005 JAK2 V617F discovery and the 2008 WHO diagnostic guideline for the JAK2 V617F mutation coincide with a 31 % increase in ET and a 21 % decrease in PV incidence rates. We found that younger women had a 13–33 % higher ET risk and that women under the age of 34 had a 58 % higher PMF risk, relative to men. Blacks, aged 35–49 with a higher ET risk, also had a 69 % higher PMF risk relative to whites.


Demographic characteristic of ET and PMF patients may be useful for improving risk prediction and informing clinical screening and treatment strategies. Changing guidelines, new discoveries, and in-depth analysis of a large population-based study have implications for accurately identifying incident cases of MPNs, MPN subgroups, and health resource planning.


Myeloproliferative neoplasm Polycythemia vera Essential thrombocythemia Primary myelofibrosis Incidence Trends 


Conflict of interest

The authors claim no conflict of interest.

Ethical standard

This research was declared exempt from the Office of Research Integrity at the University of Nevada, Reno.


  1. Alvarez-Larrán BB, Pereira A, Kerguelen A, Hernández-Boluda JC, Martínez-Avilés L et al (2014) JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events. Am J Hematol 89:517–523CrossRefPubMedGoogle Scholar
  2. Anderson LA, McMullin MF (2014) Epidemiology of MPN: what do we know. Curr Hematol Malig Rep 9:340–349CrossRefPubMedGoogle Scholar
  3. Bain BJ (2004) The World Health Organization classification of myeloproliferative and myelodysplastic syndromes. Curr Diagn Pathol 10:394–403CrossRefGoogle Scholar
  4. Bhayat F, Das-Gupta E, Smith C, McKeever T, Hubbard R (2009) The incidence of and mortality from leukaemias in the UK: a general population-based study. BMC Cancer 9:252PubMedCentralCrossRefPubMedGoogle Scholar
  5. Chasseriau J, Rivet J, Bilan F, Chomel J-C, Guilhot F, Bourmeyster N, Kitzis A (2004) Characterization of the different BCR–ABL transcripts with a single multiplex RT-PCR. J Mol Diagn 6:343–347PubMedCentralCrossRefPubMedGoogle Scholar
  6. Craig BM, Rollison DE, List AF, Cogle CR (2011) Diagnostic testing, treatment, cost of care, and survival among registered and non-registered patients with myelodysplastic syndromes. Leuk Res 35:1453–1456PubMedCentralCrossRefPubMedGoogle Scholar
  7. Craig BM, Rollison DE, List AF, Cogle CR (2012) Underreporting of myeloid malignancies by united states cancer registries. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 21:474–481Google Scholar
  8. Heisterkamp N, Stephenson JR, Groffen J, Hansen PF, de Klein A, Bartram CR, Grosveld G (1983) Localization of the c-ABL oncogene adjacent to a translocation breakpoint in chronic myelocytic leukaemia. Nature 306:239–242CrossRefPubMedGoogle Scholar
  9. Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G (1985) Structural organization of the BCR gene and its role in the Ph’ translocation. Nature 315:758–761CrossRefPubMedGoogle Scholar
  10. James C, Ugo V, Le Couedic J, Staerk J, Delhommeau F, Lacout C et al (2005) A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature 434:1144–1148CrossRefPubMedGoogle Scholar
  11. Joinpoint Regression Program, Version—February (2015) Statistical Methodology and Applications Branch, Surveillance Research Program, National Cancer InstituteGoogle Scholar
  12. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L et al (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106:2162–2168CrossRefPubMedGoogle Scholar
  13. Kim H, Fay MP, Yu B, Barrett MJ, Feuer EJ (2004) Comparability of segmented line regression models. Biometrics 60:1005–1014CrossRefPubMedGoogle Scholar
  14. Kramárová E, Stiller CA (1996) The international classification of childhood cancer. Int J Cancer 68:759–765CrossRefPubMedGoogle Scholar
  15. Kvasnicka HM (2013) WHO classification of myeloproliferative neoplasms (MPN): a critical update. Curr Hematol Malig Rep 8:333–341CrossRefPubMedGoogle Scholar
  16. Ma X, Does M, Raza A, Mayne ST (2007) Myelodysplastic syndromes: incidence and survival in the United States. Cancer 109:1536–1542CrossRefPubMedGoogle Scholar
  17. NAACCR Race and Ethnicity Work Group (2014) NAACCR Guideline for enhancing hispanic/latino identification: revised NAACCR hispanic/latino identification algorithm[NHIA v2.2.1].Springfield (IL): North American Association of Central Cancer RegistriesGoogle Scholar
  18. National Cancer Institute (2013) SEER (Surveillance, Epidemiology and End Results). Accessed 15 December 2014
  19. NCI. Cancer Trends Progress Report-2011/2012 Update (2012) National Cancer Institute, NIH, DHHS, Bethesda, MD Accessed 14 December 2014
  20. Price GL, Davis KL, Karve S, Pohl G, Walgren RA (2014) Survival patterns in United States (US) medicare enrollees with non-CML myeloproliferative neoplasms (MPN). PLoS One. 9(3):e90299PubMedCentralCrossRefPubMedGoogle Scholar
  21. Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD et al (2008) Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorder in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 112:45–52CrossRefPubMedGoogle Scholar
  22. SAS/STAT software, Version 9.3 of the SAS System for PC. (2014) SAS Institute Inc., Cary, NC, USAGoogle Scholar
  23. SEER (2015) Fast stats: an interactive tool for access to SEER cancer statistics. Surveillance Research Program, National Cancer Institute. Accessed 10 March 2015
  24. Selinger HA, Ma X (2009) Jakking up tumor registry reporting of the myeloproliferative neoplasms. Am J Hematol 84:124–126CrossRefPubMedGoogle Scholar
  25. Spivak JL, Silver RT (2008) The revised WHO Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood 112:231–239CrossRefPubMedGoogle Scholar
  26. Staerk J, Constantinescu SN (2012) The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspective. JAK-STAT 1:184–190PubMedCentralCrossRefPubMedGoogle Scholar
  27. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P (2005) International classification of childhood cancer, third edition. Cancer 103:1457–1467CrossRefPubMedGoogle Scholar
  28. Surveillance, Epidemiology, and End Results (SEER) Program ( SEER*Stat Database: incidence—SEER 9 Regs Research Data, Nov 2013 Sub (1973–2011) <Katrina/Rita Population Adjustment>- Linked To County Attributes—Total US, 1969-2012 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2014, based on the November 2013 submission. Accessed 16 Sept 2014
  29. Swerdlow AJ, Schoemaker MJ, Higgins CD, Wright AF, Jacobs PA (2008) Cancer risk in patients with constitutional chromosome deletions: a nationwide British cohort study. Br J Cancer 98:1929–1933PubMedCentralCrossRefPubMedGoogle Scholar
  30. Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson Ch et al (2014) CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 28:1472–1477CrossRefPubMedGoogle Scholar
  31. Titmarsh GL, Duncombe AS, McMullin MF, O’Rorke M, Mesa R, De Vocht F et al (2014) How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am J Hematol 112:581–587CrossRefGoogle Scholar
  32. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al (2009) The 2008 revision of the world health organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937–951CrossRefPubMedGoogle Scholar
  33. Yacoub A, Odenike O, Verstovsek S (2014) Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms. Curr Hematol Malig Rep 9:350–359PubMedCentralCrossRefPubMedGoogle Scholar
  34. Zhang SP, Li H, Lai RS (2015) Detection of JAK2 V617F mutation increases the diagnosis of myeloproliferative neoplasms. Oncol Lett 9:735–738PubMedCentralPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.School of Community Health SciencesUniversity of NevadaRenoUSA
  2. 2.Biology DepartmentTruckee Meadows Community CollegeRenoUSA

Personalised recommendations